Now live: Pro — the full 13F research suite for serious investorsSee pricing →
ACUTA CAPITAL PARTNERS, LLC

Q2 2023 · 13F-HR

ACUTA CAPITAL PARTNERS, LLCholdings as filed

Filed 2023-08-14 · accession 0001104659-23-090924

$147.6M
Reported value
35
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$27.1M18.4%297,596CommonSOLE
00032Q104WHWKAADI BIOSCIENCES INC$12.6M8.57%1,849,402CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$8.5M5.75%970,000CommonSOLE
50127T109KURAKURA ONCOLOGY INC. COMMON STOCK$7.5M5.08%709,118CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$6.3M4.25%299,841CommonSOLE
254604101IRONDISC MEDICINE INC$6.2M4.20%139,500CommonSOLE
92243G108PCVXVAXCYTE INC$6.1M4.13%122,166CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$6.1M4.12%306,194CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$5.3M3.62%224,707CommonSOLE
46583P102IVERIC BIO INC$5.2M3.50%131,454CommonSOLE
04016X101ARGXARGENX SE$4.9M3.32%12,568CommonSOLE
74006W108PRAXIS PRECISION MEDICINES I$4.9M3.31%4,250,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$4.8M3.27%147,318CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC. COMMON STOCK$4.7M3.19%430,000CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC$4.2M2.81%122,343CommonSOLE
185634102CLNNEURCLENE INC$3.7M2.53%4,240,846CommonSOLE
45175G108IKENA ONCOLOGY INC$3.7M2.48%558,000CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$3.3M2.25%382,000CommonSOLE
G3855L106GHRSGH RESEARCH PLC$2.9M1.97%244,828CommonSOLE
45258J102IMVTIMMUNOVANT INC$2.7M1.82%141,755CommonSOLE
92337C203VSTMVERASTEM INC$2.2M1.51%300,000CommonSOLE
G76279101ROIVROIVANT SCIENCES LTD$2.2M1.50%220,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$2.1M1.44%104,500CommonSOLE
G01767105ALKSALKERMES PLC$1.4M0.95%44,689CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS$1.3M0.85%121,692CommonSOLE
43157M102HILLEVAX INC$1.1M0.73%63,078CommonSOLE
61775R105MORFUSDMORPHIC HOLDING INC$1.0M0.68%17,500CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS INC$980,6500.66%27,500CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$955,5000.65%105,814CommonSOLE
09077A106BMEABIOMEA FUSION INC$878,0000.59%40,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$821,2500.56%73,000CommonSOLE
76200L309RZLTREZOLUTE INC$739,3320.50%373,400CommonSOLE
805111101SVRASAVARA INC$633,0540.43%198,139CommonSOLE
50107A104KRON1USDKRONOS BIO INC$541,8000.37%315,000CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$15,0230.01%90,832CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.